Translational Core for Therapeutic and Diagnostic Development
- Institution
- UNIVERSITY OF ILLINOIS AT CHICAGO, IL
- Principal investigator
- James Jason Mcanany
- Funding
- $100K
- Duration
- 1997–2026
Moonbase score
Still being scored
Abstract
PROJECT SUMMARY: TRANSLATIONAL CORE FOR THERAPEUTIC AND DIAGNOSTIC DEVELOPMENT The Translational Core for Therapeutic and Diagnostic Development (TCTDD) will enhance the research programs of a growing number of R01 funded investigators engaged in basic science research by providing powerful new data science and high throughput data analysis support. Currently, NEI R01 grants supported by this P30 grant are engaged in basic biomedical research (T0 research) with explicitly stated goals of translation of research findings for new methods of diagnosis, treatment, and prevention of eye diseases (T1 research). The TCTDD core will provide Data Science and Artificial Intelligence (AI) services for pre-processing, analysis and visualization of basic research data (molecular, cellular and imaging) to provide deeper mechanistic insights and synergistic opportunities for moving towards translational research (Aim 1). The TCTDD core will also provide technology-driven, automated services to bolster the research throughput for generating high quality, rigorous research data which will expand the breadth and depth of basic science research while accelerating related translational research (Aim 2). The long-term goal is to accelerate discoveries that easily transit from bench-to- bedside.
LOADING MOONBASE SCORE
Questions for UNIVERSITY OF ILLINOIS AT CHICAGO
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · University of Illinois at ChicagoNot yet scored
Mechanisms of Early Functional Loss in Diabetic Eye Disease
James Jason Mcanany · $437K · 2015–2030
- NIH · University of Illinois at Chicago47
MASLD protection by STAT5-regulated transcription factors
Rhonda D Kineman · $825K · 2025–2030
- NIH · University of Illinois at Chicago47
Identifying a novel pathway that regulates RA immunometabolism
Shiva Shahrara · $715K · 2022–2028